Talazoparib May Be Most Optimal for Patients with Germline or Homozygous tDDR-altered mCRPC
May 9th 2021According to findings from a subgroup analysis of the TALAPRO-1 trial, men with heavily pretreated metastatic castration-resistant prostate cancer, with germline and/or homozygous tumor DNA damage response alterations are most likely to respond to talazoparib.
LIBRETTO-001 and ARROW Trials Show Positive Data in RET Fusion–Positive Lung Cancer
April 28th 2021Jessica Bauman, MD, reviewed data from the LIBRETTO-001 and ARROW trials which show the efficacy and safety of selpercatinib and pralsetinib for the treatment of patients with RET fusion-positive lung cancer.
Afatinib Shows Encouraging Efficacy and Safety in Late Stage EGFR-Mutant NSCLC
April 8th 2021Integrating afatinib into standard-of-care chemoradiation with or without surgery demonstrated encouraging efficacy, feasibility, and safety results in patients with stage III EGFR-mutation positive non–small cell lung cancer.
Tuscano Reviews Treatment and Toxicity Management for a Patient With Classic Hodgkin Lymphoma
April 5th 2021Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.